By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

The company is also navigating activist criticism over access to Yeztugo and ongoing negotiations with Gilead, even as U.S.

Retailers in the U.S. are increasingly cautious due to tariffs and destocking inventories as cost-conscious consumers tighten ...

Brazilian state-run oil firm Petrobras said on Wednesday that chairman Pietro Mendes has resigned from the role, as well as from his seat on the board of directors. Mendes is set to become a director ...